Lipid mediators and their metabolism in the nucleus: Implications for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 30, Issue SUPPL.2, 2012, Pages

  Farooqui, Akhlaq A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Ceramide; ceramide 1 phosphate; docosanoids; eicosanoids; hydroxycholesterol; platelet activating factor; sphingosine 1 phosphate

Indexed keywords

4 HYDROXYNONENAL; ARACHIDONIC ACID; CANNABINOID RECEPTOR; CD59 ANTIGEN; CERAMIDE; CERAMIDE 1 PHOSPHATE; CHOLESTEROL; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; DOCOSANOID DERIVATIVE; ENDOCANNABINOID; GLYCEROPHOSPHOLIPID; ICOSANOID; ISOPROSTANE; LEUKOTRIENE; LIPID; LIPOXIN; LYSOPHOSPHATIDIC ACID; MARESIN; OXYGENASE; PHOSPHOLIPASE; PROSTAGLANDIN DERIVATIVE; RESOLVIN; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASTROCYTE; AUTOPHAGY; BRAIN CORTEX; BRAIN REGION; BRAIN TISSUE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DEGRADATION; ENDOPLASMIC RETICULUM STRESS; HIPPOCAMPUS; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLIC REGULATION; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNAPTOGENESIS;

EID: 84862987339     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111085     Document Type: Review

References (125)

1. Farooqui AA, Horrocks LA, Farooqui T (2000) Glyc-erophospholipids in brain: Their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids 106, 1-29. (Pubitemid 30394588)
2. Tamiya-Koizumi K (2002) Nuclear lipid metabolism and signaling. J Biochem 132, 13-22. (Pubitemid 34832265)
3. Martelli AM, Manzoli L, Cocco L (2004) Nuclear inositides: Facts and perspectives. Pharmacol Ther 101, 47-64. (Pubitemid 38068525)
4. Albi E, Micheli M, Viola-Magni MP (1996) Phospholipids and nuclear RNA. Cell Biol Int 20, 407-412. (Pubitemid 26341192)
5. Albi E, Cataldi S, Magni MV, Sartori C (2004) Plasmalo-gens in rat liver chromatin: New molecules involved in cell proliferation. J Cellular Physiol 201, 439-446. (Pubitemid 39453129)
6. Strambio-De-Castillia C, Niepel M, Rout MP (2010) The nuclear pore complex: Bridging nuclear transport and gene regulation. Nat Rev Mol Cell Biol 11, 490-501.
7. Naim B, Brumfeld V, Kapon R, Kiss V, Nevo R, Reich Z (2007) Passive and facilitated transport in nuclear pore complexes is largely uncoupled. J Biol Chem 282, 3881-3888. (Pubitemid 47084467)
8. Fahrenkrog B (2006) The nuclear pore complex, nuclear transport, and apoptosis. Can J Physiol Pharmacol 84, 279-286. (Pubitemid 44481091)
9. Hunt AN, Clark GT, Attard GS, Postle AD (2001) Highly saturated endonuclear phosphatidylcholine is synthesized in situ and colocated with CDP-choline pathway enzymes. J BioL Chem 276, 8492-8499.
10. Hunt AN (2006) Dynamic lipidomics of the nucleus. J Cell Biochem 97, 244-251. (Pubitemid 43167142)
11. Ledeen RW, Wu GS (2004) Nuclear lipids: Key signaling effectors inthe nervous system and other tissues. J Lipid Res 45, 1-8. (Pubitemid 38176609)
12. Ledeen RW, Wu GS (2006) Sphingolipids ofthe nucleus and their role in nuclear signaling. Biochim Biophys Acta 1761, 588-598. (Pubitemid 43928867)
13. Farooqui AA (2009) Hot Topics in Neural Membrane Lipi-dology, Springer, New York.
14. Farooqui AA, Horrocks LA (2007) Glycerophospholipids in the Brain: Phospholipases A2 in Neurological Disorders, Springer, New York.
15. Martelli AM, Manzoli L, Cocco L (2004) Nuclear inositides: Facts and perspectives. Pharmacol Ther 101, 47-64. (Pubitemid 38068525)
16. Luo M, Flamand N, Brock TG (2006) Metabolism of arachidonic acid to eicosanoids within the nucleus. Biochim Biophys Acta 1761, 618-625. (Pubitemid 43928863)
17. Maraldi NM, Zini N, Santi S, Manzoli FA (1999) Topology of inositol lipid signal transduction in the nucleus. J Cell Physiol 181, 203-217. (Pubitemid 29463636)
18. Martelli AM, Capitani S, Neri LM (1999) The generation of lipid signaling molecules in the nucleus. Prog Lipid Res 38, 273-308. (Pubitemid 29408247)
19. Martelli AM, Fala F, Faenza I, Billi AM, Cappellini A, Man-zoli L, Cocco L (2004) Metabolism and signaling activities of nuclear lipids. Cell Mol Life Sci 61, 1143-1156. (Pubitemid 38703744)
20. 2, C, and D in LA-N-1 cell nuclei. Reprod Nutr Dev 45, 613-631. (Pubitemid 41511885)
21. Penrose JF, Spector J, Lam BK, Friend DS, Xu K, Jack RM (1995) Purification of human lung leukotriene C4 synthase and preparation of a polyclonal antibody. Am J Respi Crit Care Med 152, 283-289.
22. Farooqui AA, Antony P, Ong WY, Horrocks LA, Freysz L (2004) Retinoic acid-mediated phospholipase A2 signaling in the nucleus. Brain Res Brain Res Rev 45, 179-195. (Pubitemid 38802870)
23. Zhu T, Gobeil F, Vazquez-Tello A, Leduc M, Rihakova L, Bossolasco M, Bkaily G, Peri K, Varma DR, Orvoine R, Chemtob S (2006) Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: A paradigm based on PGE2, PAF, and LPA1 receptors. Can Physiol Pharmacol 84, 377-391. (Pubitemid 44481100)
24. Farooqui AA, Horrocks LA (2006) Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist 12, 245-260. (Pubitemid 43725834)
25. Bazan NG (2009) Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids 81, 205-211.
26. Bazan NG (2009) Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 50, S400-S405.
27. Serhan CN (2005) Novel eicosanoid and docosanoid mediators: Resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 8, 115-121. (Pubitemid 40289470)
28. Serhan CN, Yang R, Martinod K, Kasuga K, Pilla PS, Porter TF, Oh SF, Spite M (2009) Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206, 15-23.
29. Jump DB (2004) Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 41, 41-78. (Pubitemid 38299789)
30. de Urquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J, Perlmann T (2000) Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140-2144. (Pubitemid 32001593)
31. Lengqvist J, Mata de Urquiza A, Bergman AC, Willson TM, Sjövall J, Perlmann T, Griffiths WJ (2004) Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor a ligand-binding domain. Mol Cell Proteomics 3, 692-703. (Pubitemid 39077000)
32. Pifferi F, Roux F, Langelier B, Alessandri JM, Vancassel S, Jouin M, Lavialle M, Guesnet P (2005) (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. J Nutr 135, 2241-2246. (Pubitemid 41298394)
33. Clarke SD (2000) Polyunsaturated fatty acid regulation of gene transcription: A mechanism to improve energy balance and insulin resistance. Br J Nutr 83 (Suppl 1) , S59-S66. (Pubitemid 30319083)
34. Nakamura MT, Cheon Y, Li Y, Nara TY (2004) Mechanisms of regulation of gene expression by fatty acids. Lipids 39, 1077-1083. (Pubitemid 40129050)
35. Valentine RC, Valentine DL (2004) Omega-3 fatty acids in cellular membranes: A unified concept. Prog Lipid Res 43, 383-402. (Pubitemid 39348977)
36. Bazan NG (1995) Inflammation. A signal terminator. Nature 374, 501-502.
37. Bazan NG (2003) Synaptic lipid signaling: Significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res 44, 2221-2233. (Pubitemid 38082480)
38. Honda Z, Ishii S, Shimizu T (2002) Platelet-activating factor receptor. J Biochem 131, 773-779. (Pubitemid 34717579)
39. Marrache AM, Gobeil F Jr, Bernier SG, Stankova J, Rola-Pleszczynski M, Choufani S, Bkaily G, Brourdean A, Sirois MG, Vazquez-Tello A, Fan L, Joyal JS, Filep JG, Varma DR, Ribeiro-Silva A, Chemtob S (2002) Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor. J Immunol 169, 6474-6481. (Pubitemid 36903498)
40. Farooqui AA, Horrocks LA (2008) Metabolism and Functions of Ether Lipids in Brain, Springer, New York.
41. Hostettler ME, Knapp PE, Carlson SL (2002) Platelet-activating factor induces cell death in cultured astrocytes and oligodendrocytes: Involvement of caspase-3. Glia 38, 228-239.
42. Zhang Q, Seltmann H, Zouboulis CC, Travers JB (2006) Activation of platelet-activating factor receptor in SZ95 sebocytes results in inflammatory cytokine and prostaglandin E2 production. Exp Dermatol 15, 769-774. (Pubitemid 44437353)
43. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884. (Pubitemid 37351427)
44. McIntosh HH, Song C, Howlett AC (1998) CB1 cannabinoid receptor: Cellular regulation and distribution in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 53, 163-173. (Pubitemid 28085452)
45. Chen P, Hu S, Yao J, Moore SA, Spector AA, Fang X (2005) Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 69, 28-35. (Pubitemid 40416723)
46. Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzman M (2006) Endocannabinoids: A new family of lipid mediators involved in the regulation of neural cell development. Curr PharmDes 12, 2319-2325. (Pubitemid 43891402)
47. Walter I, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141, 775-785. (Pubitemid 38446178)
48. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neu-rochem 95, 437-445. (Pubitemid 41457512)
49. Berdyshev EV (2000) Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids108, 169-190.
50. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81-128. (Pubitemid 121003917)
51. Awasthi YC, Sharma R, Cheng JZ, Yang Y, Sharma A, Singhal SS, Awasthi S (2003) Role of 4-hydroxynonenal in stress-mediated apoptosis signaling. Mol Aspects Med 24, 219-230. (Pubitemid 36945022)
52. Chen ZH, Saito Y, Yoshida Y, Sekine A, Noguchi N, Niki E (2005) 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem 280, 41921-41927. (Pubitemid 43023161)
53. Poli G, Schaur RJ (2000) 4-Hydroxynonenal in the path-omechanisms of oxidative stress. IUBMB Life 50, 315-321.
54. Lee SJ, Kim CE, Yun MR, Seo KW, Park HM, Yun JW, Shin HK, Bae SS, Kim CD (2010) 4-Hydroxynonenal enhances MMP-9 production in murine macrophages via 5-lipoxygenase-mediated activation of ERK and p38 MAPK. Toxicol Appl Pharmacol 242, 191-198.
55. Sharma R, Sharma A, Dwivedi S, Zimniak P, Awasthi S, Awasthi YC (2008) 4-Hydroxynonenal self-limits fasmediated DISC-independent apoptosis by promoting export of Daxx from the nucleus to the cytosol and its binding to Fas. Biochemistry 47, 143-156.
56. Kristal BS, Park BK, Yu BP (1996) 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem 271, 6033-6038. (Pubitemid 26095405)
57. Lee JY, Je JH, Jung KJ, Yu BP, Chung HY (2004) Induction of endothelial iNOS by 4-hydroxyhexenal through NF-κB activation. Free Radic Biol Med 37, 539-548. (Pubitemid 38901086)
58. Camandola S, Poli G, Mattson MP (2000) The lipid peroxidation product 4-hydroxy-2, 3-nonenal increases AP-1-binding activity through caspase activation in neurons. J Neurochem 74, 159-168. (Pubitemid 30012766)
59. Gerasimenko O, Gerasimenko J (2004) New aspects of nuclear calcium signalling. J Cell Sci 117, 3087-3094. (Pubitemid 39139896)
60. Odom AR, Stahlberg A, Wente SR, York JD (2000) A role for nuclear inositol 1, 4, 5-trisphosphate kinase in transcrip-tional control. Science 287, 2026-2029. (Pubitemid 30158681)
61. Evangelisti C, Bortul R, Fala F, Tabellini G, Goto K, MartelliAM (2007) Nuclear diacylglycerol kinases: Emerging downstream regulators in cell signaling networks. Histol Histopathol 22, 573-579. (Pubitemid 46647269)
62. Saino-Saito S, Hozumi Y, Goto K (2011) Excitotoxicity by kainate-induced seizure causes diacylglycerol kinase ζ to shuttle from the nucleus to the cytoplasm in hippocampal neurons. Neurosci Lett 494, 185-189.
63. Ledeen RW, Wu G (2008) Nuclear sphingolipids: Metabolism and signaling. J Lipid Res 49, 1176-1186.
64. Scassellati C, Albi E, Cmarko D, Tiberi C, Cmarkova J, Bouchet-Marquis C, Verschure PJ, Driel R, Magni MV, Fakan S (2010) Intranuclear sphingomyelin is associated with transcriptionally active chromatin and plays a role in nuclear integrity. Biol Cell 102, 361-375.
65. Wang J, Wu G, Miyagi T, Lu ZH, Ledeen RW (2009) Siali-dase occurs in both membranes of the nuclear envelope and hydrolyzes endogenous GD1a. J Neurochem 111, 547-554.
66. Albi E, Lazzaarini R, Viola Magni M (2008) Phosphatidylcholine/ sphingomyelin metabolism crosstalk inside the nucleus. Biochem J 410, 381-389. (Pubitemid 351346196)
67. Ledeen RW, Wu G (2006) GM1 ganglioside: Another nuclear lipid that modulates nuclear calciumGM1 potentiates the nuclear sodium-calcium exchanger. Can J Physiol Pharmacol 84, 393-402. (Pubitemid 44481101)
68. Cremesti A, Paris F, Grassme H, Holler N, Tschopp J, Fuks Z, Gulbins E, Kolesnick R (2001) Ceramide enables fas to cap and kill. J Biol Chem 276, 23954-23961. (Pubitemid 37410795)
69. Gulbins E, Kolesnick R (2003) Raft ceramide in molecular medicine. Oncogene 22, 7070-7077. (Pubitemid 37386676)
70. Birbes H, Luberto C, Hsu Y, El Bawab S, Hannun Y, Obeid L (2005) A mitochondrial pool of sphingomyelin is involved in TNFa-induced Bax translocation to mitochondria. Biochem J 386, 445-451. (Pubitemid 40445868)
71. Adam-Klages S, Schwandner R, Adam D, Kreder D, Bernardo K, Kronke M (1998) Distinct adapter proteins mediate acid versus neutral sphingomyelinase activation through the p55 receptor for tumor necrosis factor. JLeukoc Biol 63, 678-682.
72. Beckman M, Kihlmark M, Iverfeldt K, Hallberg E (2004) Degradation of GFP-labelled POM121, a non-invasive sensor of nuclear apoptosis, precedes clustering of nuclear pores and externalisation of phosphatidylserine. Apoptosis 9, 363-368. (Pubitemid 38981510)
73. Kamada S, Kikkawa U, Tsujimoto Y, Hunter T (2005) A-kinase-anchoring protein 95 functions as a potential carrier for the nuclear translocation of active caspase 3 through an enzyme-substrate-like association. Mol Cell Biol 25, 9469-9477. (Pubitemid 41507847)
74. Jaattela M, Wissing D, Kokholm K, Kallunki T, Egeblad M (1998) Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J17, 6124-6134. (Pubitemid 28497786)
75. Ruvolo PP (2001) Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 15, 1153-1160. (Pubitemid 32776437)
76. Donati C, Bruni P (2006) Sphingosine 1-phosphate regulates cytoskeleton dynamics: Implications in its biological response. Biochim Biophys Acta 1758, 2037-2048. (Pubitemid 44879361)
77. Singh IN, Hall ED (2008) Multifaceted roles of sphingosine-1-phosphate: How does this bioactive sphingolipid fit with acute neurological injury? J Neurosci Res 86, 1419-1433. (Pubitemid 351642437)
78. Siehler S, Wang Y, Fan X, Windh RT, Manning DR (2001) Sphingosine 1-Phosphate Activates Nuclear Factor-KB through Edg Receptors activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells. J Biol Chem 276, 48733-48739.
79. Windh RT, Lee MJ, Hla T, An S, Barr AJ, Manning DR (1999) Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 families of heterotrimeric G proteins. J Biol Chem 274, 27351-27358.
80. Ding G, Sonoda H, Yu H, Kajimoto T, Goparaju SK, Jahangeer S, Okada T, Nakamura S (2007) Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J Biol Chem 282, 27493-27502. (Pubitemid 47501982)
81. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poul-ton S, Milstien S, Kohama T, Spiegel S (2000) Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. JBiol Chem 275, 19513-19520. (Pubitemid 30441543)
82. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325, 1254-1257.
83. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, Shi Y, Chen Y, Meng A, Feng XH (2006) PPM1A functions as a Smad phosphatase to terminate TGFβ signaling. Cell 125, 915-928. (Pubitemid 43795197)
84. Jurevics H, Morell P (1995) Cholesterol for synthesis of myelin is made locally, not imported into brain. JNeurochem 64, 895-901.
85. Dietschy JM, Turley SD (2004) Thematic review series: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45, 1375-1397. (Pubitemid 39022664)
86. Simons K, Ikonen E (2000) How cells handle cholesterol. Science 290, 1721-1726. (Pubitemid 32004797)
87. Bjorkhem I, Cedazo-Minguez A, Leoni V, Meaney S (2009) Oxysterols and neurodegenerative diseases. Mol Aspect Med 30, 171-179.
88. Björkhem I, Lütjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J (1998) Cholesterol homeostasis inhuman brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39, 1594-1600. (Pubitemid 28377923)
89. Zhao C, Dahlman-Wright K (2010) Liver X receptor in cholesterol metabolism. J Endocrinol 204, 233-240.
90. Zelcer N, Tontonoz P (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116, 607-614. (Pubitemid 43326865)
91. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, Rosenfeld MG, Glass CK (2007) Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 25, 57-70. (Pubitemid 46049061)
92. Kolsch H, Ludwig M, Lutjohann D, Rao ML (2001) Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J Neural Transm 108, 475-488. (Pubitemid 32703896)
93. Chang JY, Chavis JA, Liu LZ, Drew PD (1998) Cholesterol oxides induce programmed cell death in microglial cells. Biochem Biophys Res Commun 249, 817-821. (Pubitemid 28441921)
94. Lizard G, Miguet C, Bessède, G, Monier S, Gueldry S, Neel D, Gambert P (2000) Impairment with various antioxidants of the loss of mitochondrial transmembrane potential and of the cytosolic release of cytochrome c occur-ing during 7-ketocholesterol-induced apoptosis. Free Radic Biol Med 28, 743-753. (Pubitemid 30171288)
95. Farooqui AA (2010) Neurochemical Aspects of Neurotrau-matic and Neurodegenerative Disease, Springer, New York.
96. Farooqui AA (2011) Lipid Mediators and their metabolism in the Brain, Springer, New York.
97. Farooqui AA, Ong WY, Horrocks LA (2006) Inhibitors of brain phospholipase A2 activity: Their neuropharmacolog-ical effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58, 591-620. (Pubitemid 44403685)
98. Phillis JW, Horrocks LA, Farooqui AA (2006) Cyclooxyge-nases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Res Rev 52, 201-243. (Pubitemid 44291802)
99. Han X, Holtzman D, McKeel DW Jr, Kelley J, Morris JC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J Neurochem 82, 809-818.
100. Qin WP, Ho L, Pompl PN, Peng YZ, Zhao Z, Xiang ZM, Robakis NK, Shioi J, Suh J, Pasinetti GM (2003) Cyclooxygenase (COX) -2 and COX-1 potentiate β-amyloid peptide generation through mechanisms that involve -y-secretase activity. J Biol Chem 278, 50970-50977. (Pubitemid 38020330)
101. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31, 398-408.
102. Lutjohann D, von Bergmann K (2003) 24S-hydroxy-cholesterol: A marker of brain cholesterol metabolism. Pharmacopsychiatry 36 (Suppl. 2) , S102-S106. (Pubitemid 37346639)
103. Kanfer JN, Sorrentino G, Sitar DS (1998) Phospholipases as mediators of amyloid beta peptide neurotoxicity: An early event contributing to neurodegeneration characteristic of Alzheimer's disease. Neurosci Lett 257, 93-96. (Pubitemid 28552896)
104. Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA (2011) Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer's disease pathology. Prog LipidRes 50, 313-330.
105. Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospho-lipase A2 in the central nervous system: Implications for neurodegenerative diseases. J Lipid Res 45, 205-213. (Pubitemid 38228817)
106. Jayadev S, Hayter HL, Andrieu N, Gamard CJ, Liu B, Balu R, Hayakawa M, Ito F, Hannun YA (1997) Phospholipase A2 is necessary for tumor necrosis factor a-induced ceramide generation in L929 cells. J Biol Chem 272, 17196-17203. (Pubitemid 27289833)
107. Pettus BJ, Kitatani K, Chalfant CE, Taha TA, Kawamori T, Bielawski J, Obeid LM, Hannun YA (2005) The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol Pharmacol 68, 330-335. (Pubitemid 41058296)
108. Cutler RJ, Kelley J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101, 2070-2075. (Pubitemid 38229016)
109. Bazan NG, Colangelo V, Lukiw WJ (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 68-69, 197-210. (Pubitemid 35247397)
110. Manev H, Uz T, Qu TY (2000) 5-Lipoxygenase and cyclooxygenase mRNA expression in rat hippocampus: Early response to glutamate receptor activation by kainite. Exp Gerontol 35, 1201-1209.
111. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veer-huis R, Eikelenboom P (2008) Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr PharmDes 14, 1419-1427. (Pubitemid 351982549)
112. Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87, 319-324. (Pubitemid 28370892)
113. Shimohama S, Sasaki Y, Fujimoto S, Kamiya S, Taniguchi T, Takenawa T, Kimura J (1998) Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease. Neuroscience 82, 999-1007. (Pubitemid 27502045)
114. Zhang D, Dhilion H, Prasad MR, Markesbery MR (1998) Regional levels of brain phospholipase Cgamma in Alzheimer's disease. Brain Res 811, 161-165. (Pubitemid 29003378)
115. Farooqui AA (2011) Oxidative stress in kainic acid neurotoxicity: Implications for the pathogenesis of neu-rotraumatic and neurodegenerative diseases In Molecular Aspects of Oxidative Stress on Cell Signaling in Vertebrate and Invertebrate, Farooqui T, Farooqui A.A. Eds. Wiley-Blackwell Publishers (In press).
116. Sidell KR, Montine KS, Picklo MJ Sr, Olsen SJ, Amarnath V, Montine TJ (2003) Mercapturate metabolism of 4-hydroxy-2-nonenal in rat and human cerebrum. J Neuropathol Exp Neurol 62, 146-153. (Pubitemid 36176949)
117. Mantha AK, Moorthy K, Cowsik SM, Baquer NZ (2006) Neuroprotective role of neurokinin B (NKB) on beta-amyloid (25-35) induced toxicity in aging rat brain synaptosomes: Involvement in oxidative stress and excito-toxicity. Biogerontology 7, 1-17. (Pubitemid 44026968)
118. Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, Smith MA (2002) IsAlzheimer's diseaseamitochondrial disorder? Neuroscientist 8, 489-496.
119. Reddy PH, Beal MF (2005) Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 49, 618-632. (Pubitemid 41546661)
120. Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, van Kamp GJ, Scheltens P, SchefferPG (2003) Decreased lysophosphatidylcholine/ phosphatidylcholine ratio in cere-brospinal fluid inAlzheimer's disease.J Neural Transm110, 949-955. (Pubitemid 36981409)
121. Farroqui AA, Liss L, HorrocksLA (1990) Elevated activities of lipases and lysophospholipases in Alzheimer's disease. Dementia 1, 208-214.
122. McLamon JG, Choi HB, Lue LF, Walker DG, Kim SU (2005) Perturbations in calciummediated signal trans-duction in microglia from Alzheimer's disease patients. J Neurosci Res 81, 426-435. (Pubitemid 41359297)
123. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neu-ritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23, 11136-11141. (Pubitemid 37548949)
124. Bradley MA, Markesbery WR, Lovell MA (2010) Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med 48, 1570-1576.
125. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52, 562-565. (Pubitemid 29075604)